Castle Biosciences, Inc. (CSTL) fair value analysis
Nasdaq · Updated 2026-10-19
CSTL price how computed
Valuation status
No fair-value estimate yetCSTL has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for CSTL yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $31.96
- Sector
- Healthcare
- 12-month range
- $18.15–$43.04
- Market cap
- $976M
- From 52-week high
- -25.7%
- Shares outstanding
- 30.5M
- Rank in Healthcare by quality score
- #50 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Castle Biosciences is a molecular diagnostics company that develops and commercializes diagnostic tests designed to help physicians make treatment decisions for patients with cancer. The company operates primarily in the United States and serves the oncology market through its proprietary testing platforms.
CSTL currently ranks #50 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $976M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $357M
- Net margin
- -5.4%
- EPS (TTM)
- $-0.66
- Gross margin
- 77.1%
- Debt / equity
- 0.08
- Revenue growth (3-yr avg)
- 22.8%
- Shares outstanding
- 30.5M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
- 50-day average
- $33.54
- 200-day average
- $28.78
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+84.1%)
2026-03 ▬ met (0.0%)
2025-12 ▲ beat (+65.2%)
2025-09 ▲ beat (+96.1%)
2025-06 ▲ beat (+130.0%)
2025-03 ▼ miss (-1185.7%)
2024-12 ▲ beat (+700.0%)
2024-09 ▲ beat (+700.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 0 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $45.2
- Target vs last price
- +41.4%
What our data shows for CSTL
- Shares are trading in the middle of their 12-month price range of $18.15–$43.04.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CSTL's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CSTL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — CSTL's 50/200-day trend state shifted from uptrend to mixed this week, reflecting a change in its near-term momentum relative to longer-term direction. The stock remains in the Healthcare sector with a valuation verdict currently awaiting full assessment. This trend transition suggests reduced clarity in CSTL's directional momentum compared to the previous week's uptrend characterization.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for CSTL showed a decline in the quality grade this week, dropping from A to B. The stock remains in the Healthcare sector with a valuation verdict currently awaiting full valuation assessment.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CSTL stock undervalued?
TickrTrends has no fair-value estimate for CSTL yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is CSTL's TickrTrends verdict?
CSTL is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does CSTL compare to other Healthcare stocks?
CSTL ranks #50 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CSTL overbought or oversold?
CSTL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CSTL report earnings next?
CSTL's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does CSTL usually beat earnings estimates?
Over its last 8 reported quarters CSTL beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CSTL?
Of 9 analysts covering CSTL, 9 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $45.2 (+41.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.